What type of study is this?

This is a Human Clinical Trial study.

September 17, 2025

Deuterium metabolic imaging in epilepsy patients at 7T

Key Points

No significant metabolic differences were found between the epileptogenic zone and the contralateral region during the interictal phase.
Dynamic deuterium metabolic imaging showed increased levels of both 2H-Glc and 2H-Glx over time in patients.
Five patients with MRI-negative epilepsy underwent this non-invasive imaging technique at 7 Tesla.
The findings underscore DMI's potential role in improving diagnostics for epilepsy, particularly in post-ictal imaging.

Abstract

Motivation: Identifying the epileptogenic zone (EZ) in MRI-negative epilepsy patients is crucial for surgical success. Goal(s): To investigate whether dynamic deuterium metabolic imaging (DMI) can detect subtle metabolic disturbances in MRI-negative epilepsy patients. Approach: Five patients consumed 6,6'-2H2glucose, and underwent dynamic DMI at 7 Tesla to track 2H-Glc (glucose) and 2H-Glx (glutamate/glutamine) levels in the epileptogenic zone (EZ) and non-epileptogenic contralateral region. Results: Both 2H-Glc and 2H-Glx levels increased over time, but no significant metabolic differences were observed between EZ and the contralateral region in the interictal phase. Impact: Dynamic DMI offers a non-invasive approach to assess epilepsy metabolism. Although this study observed no metabolic differences between the epileptogenic-zone and contralateral normal-appearing brain tissue interictally, DMI should be considered for direct post-ictal imaging, potentially aiding diagnosis in MRI-negative epilepsy.

Ask AI

Helpful

Bookmark